STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 507 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 507 shares of the stock in a transaction dated Monday, November 13th. The stock was acquired at an average cost of $33.04 per share, with a total value of $16,751.28. Following the transaction, the insider now directly owns 10,102,844 shares in the company, valued at $333,797,965.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, November 10th, Broadwood Partners, L.P. acquired 34,320 shares of STAAR Surgical stock. The stock was acquired at an average cost of $32.73 per share, with a total value of $1,123,293.60.
• On Wednesday, November 8th, Broadwood Partners, L.P. acquired 139,409 shares of STAAR Surgical stock. The stock was acquired at an average cost of $33.71 per share, with a total value of $4,699,477.39.
• On Monday, November 6th, Broadwood Partners, L.P. purchased 164,607 shares of STAAR Surgical stock. The shares were purchased at an average cost of $34.16 per share, with a total value of $5,622,975.12.
• On Thursday, November 2nd, Broadwood Partners, L.P. purchased 144,027 shares of STAAR Surgical stock. The shares were purchased at an average cost of $35.79 per share, with a total value of $5,154,726.33.
• On Friday, October 6th, Broadwood Partners, L.P. purchased 75,299 shares of STAAR Surgical stock. The shares were purchased at an average cost of $37.62 per share, with a total value of $2,832,748.38.
• On Wednesday, October 4th, Broadwood Partners, L.P. purchased 32,523 shares of STAAR Surgical stock. The shares were purchased at an average cost of $37.93 per share, with a total value of $1,233,597.39.
• On Thursday, September 21st, Broadwood Partners, L.P. purchased 154,814 shares of STAAR Surgical stock. The shares were purchased at an average cost of $39.62 per share, with a total value of $6,133,730.68.
• On Tuesday, September 19th, Broadwood Partners, L.P. acquired 4,490 shares of STAAR Surgical stock. The stock was bought at an average cost of $40.89 per share, with a total value of $183,596.10.
• On Thursday, September 7th, Broadwood Partners, L.P. acquired 60,874 shares of STAAR Surgical stock. The stock was bought at an average cost of $41.26 per share, with a total value of $2,511,661.24.
• On Tuesday, September 5th, Broadwood Partners, L.P. acquired 20,144 shares of STAAR Surgical stock. The stock was bought at an average cost of $41.87 per share, with a total value of $843,429.28.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $36.05 on Thursday. The stock has a market cap of $1.76 billion, a P/E ratio of 92.44 and a beta of 1.05. The stock’s 50 day simple moving average is $39.94 and its 200-day simple moving average is $48.62. STAAR Surgical has a 1-year low of $32.47 and a 1-year high of $81.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jupiter Asset Management Ltd. acquired a new position in shares of STAAR Surgical during the 1st quarter worth approximately $1,544,000. Legacy Advisors LLC boosted its holdings in shares of STAAR Surgical by 5.0% during the 2nd quarter. Legacy Advisors LLC now owns 5,650 shares of the medical instruments supplier’s stock worth $297,000 after purchasing an additional 268 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of STAAR Surgical by 28.2% during the 1st quarter. Zions Bancorporation N.A. now owns 9,517 shares of the medical instruments supplier’s stock worth $609,000 after purchasing an additional 2,091 shares during the last quarter. Linden Thomas Advisory Services LLC acquired a new position in shares of STAAR Surgical during the 2nd quarter worth approximately $1,043,000. Finally, LPL Financial LLC boosted its holdings in shares of STAAR Surgical by 39.5% during the 2nd quarter. LPL Financial LLC now owns 31,202 shares of the medical instruments supplier’s stock worth $1,640,000 after purchasing an additional 8,827 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent analyst reports. Benchmark lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Needham & Company LLC cut their price target on STAAR Surgical from $52.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, November 2nd. Stephens restated an “overweight” rating and issued a $57.00 price target on shares of STAAR Surgical in a research note on Monday, August 14th. Canaccord Genuity Group restated a “hold” rating and issued a $48.00 price target (down previously from $77.00) on shares of STAAR Surgical in a research note on Thursday, August 3rd. Finally, Piper Sandler cut their price target on STAAR Surgical from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, November 2nd. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $54.33.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.